Aim: Chemotherapeutic agents have been shown to increase lung patient survival, however
their use may be limited by their serious adverse effects. We aimed to assess int impact of …

Abstract What is Known and Objective Solute Carrier (SLC) transporters are known
mediators of drug disposition that facilitate the influx of substrates and various …

Chemotherapeutic drugs are underutilized in lung cancer management due in part to
serious adverse drug reactions (ADRs). Aim: With studies revealing an association between …

Background: Organic cation transporter 6 (OCT6) encoded by solute carrier family 22
member 16 (SLC22A16) is involved in regulating cellular sensitivity and resistance to …

Several polymorphisms in the genes involved in drug metabolism or elimination are known
to be associated with pharmacokinetic or pharmacodynamic variability, but their correlations …

Background Docetaxel is a widely used cytotoxic agent for treatments of various cancers.
The ATP binding cassette (ABC) transporter/multidrug resistance protein (MRP) …

Background Genetic polymorphisms contribute toward interindividual variations in drug
response. We investigated the effects of genetic polymorphisms on the clinical outcome of …

Purpose Dose-limiting toxicities of docetaxel are widely considered to be neutropenia,
anemia, skin toxicity, and nausea. One of the factors that limit the use of docetaxel is its …

Purpose Methotrexate plasma concentration is related to its clinical effects. Our aim was to
identify the genetic basis of interindividual variability in methotrexate pharmacokinetics in …

To define an integrated pharmacogenetic model for predicting irinotecan pharmacokinetic
(PK) and severe toxicity, we evaluated multivariate analysis using 15 polymorphisms within …